Cargando…

Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy

BACKGROUND: Pharmaco-invasive therapy (PIT), combining thrombolysis and percutaneous coronary intervention, was a potential complement for primary percutaneous coronary intervention (pPCI), while bleeding risk was still a concern. OBJECTIVES: This study aims to compare the efficacy and safety outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Kaiyin, Zhang, Bin, Zheng, Bo, Zhang, Yan, Huo, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970601/
https://www.ncbi.nlm.nih.gov/pubmed/35369319
http://dx.doi.org/10.3389/fcvm.2022.813325
_version_ 1784679491775234048
author Li, Kaiyin
Zhang, Bin
Zheng, Bo
Zhang, Yan
Huo, Yong
author_facet Li, Kaiyin
Zhang, Bin
Zheng, Bo
Zhang, Yan
Huo, Yong
author_sort Li, Kaiyin
collection PubMed
description BACKGROUND: Pharmaco-invasive therapy (PIT), combining thrombolysis and percutaneous coronary intervention, was a potential complement for primary percutaneous coronary intervention (pPCI), while bleeding risk was still a concern. OBJECTIVES: This study aims to compare the efficacy and safety outcomes of PIT and pPCI. METHODS: A systematic search for randomized controlled trials (RCTs) and observational studies were conducted on Pubmed, Embase, Cochrane library, and Scopus. RCTs and observational studies were all collected and respectively analyzed, and combined pooled analysis was also presented. The primary efficacy outcome was short-term all-cause mortality within 30 days, including in-hospital period. The primary safety outcome was 30-day trial-defined major bleeding events. RESULTS: A total of 26,597 patients from 5 RCTs and 12 observational studies were included. There was no significant difference in short-term mortality [RCTs: risk ratio (RR): 1.14, 95% CI: 0.67–1.93, I(2) = 0%, p = 0.64; combined results: odds ratio (OR): 1.09, 95% CI: 0.93–1.29, I(2) = 0%, p = 0.30] and 30-day major bleeding events (RCTs: RR: 0.44, 95% CI: 0.07–2.93, I(2) = 0%, p = 0.39; combined results: OR: 1.01, 95% CI: 0.53–1.92, I(2) = 0%, p = 0.98). However, pPCI reduced risk of in-hospital major bleeding events, stroke and intracranial bleeding, but increased risk of in-hospital heart failure and 30-day heart failure in combined analysis of RCTs and observational studies, despite no significant difference in analysis of RCTs. CONCLUSION: Pharmaco-invasive therapy could be an important complement for pPCI in real-world clinical practice under specific conditions, but studies aiming at optimizing thrombolysis and its combination of mandatory coronary angiography are also warranted.
format Online
Article
Text
id pubmed-8970601
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89706012022-04-01 Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy Li, Kaiyin Zhang, Bin Zheng, Bo Zhang, Yan Huo, Yong Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Pharmaco-invasive therapy (PIT), combining thrombolysis and percutaneous coronary intervention, was a potential complement for primary percutaneous coronary intervention (pPCI), while bleeding risk was still a concern. OBJECTIVES: This study aims to compare the efficacy and safety outcomes of PIT and pPCI. METHODS: A systematic search for randomized controlled trials (RCTs) and observational studies were conducted on Pubmed, Embase, Cochrane library, and Scopus. RCTs and observational studies were all collected and respectively analyzed, and combined pooled analysis was also presented. The primary efficacy outcome was short-term all-cause mortality within 30 days, including in-hospital period. The primary safety outcome was 30-day trial-defined major bleeding events. RESULTS: A total of 26,597 patients from 5 RCTs and 12 observational studies were included. There was no significant difference in short-term mortality [RCTs: risk ratio (RR): 1.14, 95% CI: 0.67–1.93, I(2) = 0%, p = 0.64; combined results: odds ratio (OR): 1.09, 95% CI: 0.93–1.29, I(2) = 0%, p = 0.30] and 30-day major bleeding events (RCTs: RR: 0.44, 95% CI: 0.07–2.93, I(2) = 0%, p = 0.39; combined results: OR: 1.01, 95% CI: 0.53–1.92, I(2) = 0%, p = 0.98). However, pPCI reduced risk of in-hospital major bleeding events, stroke and intracranial bleeding, but increased risk of in-hospital heart failure and 30-day heart failure in combined analysis of RCTs and observational studies, despite no significant difference in analysis of RCTs. CONCLUSION: Pharmaco-invasive therapy could be an important complement for pPCI in real-world clinical practice under specific conditions, but studies aiming at optimizing thrombolysis and its combination of mandatory coronary angiography are also warranted. Frontiers Media S.A. 2022-03-17 /pmc/articles/PMC8970601/ /pubmed/35369319 http://dx.doi.org/10.3389/fcvm.2022.813325 Text en Copyright © 2022 Li, Zhang, Zheng, Zhang and Huo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Li, Kaiyin
Zhang, Bin
Zheng, Bo
Zhang, Yan
Huo, Yong
Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
title Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
title_full Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
title_fullStr Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
title_full_unstemmed Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
title_short Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy
title_sort reperfusion strategy of st-elevation myocardial infarction: a meta-analysis of primary percutaneous coronary intervention and pharmaco-invasive therapy
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970601/
https://www.ncbi.nlm.nih.gov/pubmed/35369319
http://dx.doi.org/10.3389/fcvm.2022.813325
work_keys_str_mv AT likaiyin reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy
AT zhangbin reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy
AT zhengbo reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy
AT zhangyan reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy
AT huoyong reperfusionstrategyofstelevationmyocardialinfarctionametaanalysisofprimarypercutaneouscoronaryinterventionandpharmacoinvasivetherapy